Speaker

Michael Gendreau

Chief Medical Officer, Dogwood Therapeutics

Michael Gendreau, Chief Medical Officer at Dogwood Therapeutics, spoke at Ion Channel-Targeted Drug Development Summit (Boston, United States of America, 23–24 Sept 2026) in the session “Selective Sodium Channel Modulation to Deliver Meaningful Clinical Benefits in Chronic Chemotherapy-Induced Neuropathic Pain”.

Conferences: 1
Keynotes: 0
Upcoming: 0

Pharmacy & Pharmaceutical Sciences

Past appearances

Ion Channel-Targeted Drug Development Summit
23–24 Sept 2026Boston, United States of America
- SpeakerSelective Sodium Channel Modulation to Deliver Meaningful Clinical Benefits in Chronic Chemotherapy-Induced Neuropathic Pain
- PanelFireside Chat: Reflecting on Clinical Experience to Shape Next‑Generation Ion Channel ProgramsWith Jim Ellis

More speakers at Ion Channel-Targeted Drug Development Summit

Christopher Ahern
Professor - Molecular Physiology & Biophysics, The University of Iowa
Alejandro Amador
Vice President of R&D and Operations, Navega Therapeutics
Bruce Bean
Professor of Neurobiology, Harvard Medical School
Gulayse Dunn
Senior Principal Scientist, Novartis
Dan Elbaum
Chief Scientific Officer, QurAlis Corp.
Kelly Gatfield
Group Leader & Scientific Leader, GlaxoSmithKline

See all 19 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Michael Gendreau, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].